Trial reportJournal of robotic surgery2025
A novel robotic system based on heterogeneous master-slave control algorithm: design and its clinical application in endoscopic submucosal dissection.
Trial report in Journal of robotic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Robotic-assisted endoscopic submucosal dissection for superficial gastrointestinal neoplasms: a bayesian meta-analysis & systematic review.Journal of robotic surgery · 2026Pooled it
- Robotic-assisted endoscopic submucosal dissection: a scoping review of preclinical and early clinical evidence.Surgical endoscopy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Endoscopic Submucosal Dissection (ESD) is the gold standard for early gastrointestinal tumor resection but remains technically demanding due to limitations in visualization, traction, and instrument control. A flexible auxiliary single-arm transluminal endoscopic robot (FASTER, EndoFaster) was therefore developed to provide real-time traction assistance. The EndoFaster system underwent a two-stage validation. Technical assessment confirmed real-time control performance, including motion latency, trajectory fidelity, and positional accuracy. Subsequently, a prospective, randomized multicenter trial across six hospitals enrolled 192 ESD patients, randomized 1:1 to robotic-assisted ESD or conventional ESD. Primary endpoint was en bloc (R0) resection rate; secondary endpoints included dissection time, submucosal visualization, intraprocedural complications, and operator workload. EndoFaster achieved stable, accurate motion performance, systems validation confirmed precise real-time motion mapping between master-slave controllers within clinically acceptable thresholds. In multicenter clinical trials, en bloc resection rates were comparable between the EndoFaster (98.84%) and control groups (98.13%), confirming non-inferiority. The system significantly reduced dissection time (P = 0.00435), improved submucosal visualization, and decreased muscular injury incidence and operator workload. The EndoFaster robotic assistance system serves as a dynamic "third hand," effectively enhancing submucosal visualization and traction control. This improves the safety and efficiency of ESD while preserving standard clinical workflows.
Indexed as
Identifiers
40970995What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.